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IL-5 links adaptive and natural immunity in reducing
atherosclerotic disease
Alan Daugherty, … , Debra L. Rateri, Victoria L. King
J Clin Invest. 2004;114(3):317-319. https://doi.org/10.1172/JCI22561.
Commentary

Oxidized LDL induces changes in several facets of the immune system, although the relationships between these facets
and their contributions to atherogenesis have yet to be fully elucidated. A report in this issue of the JCI provides a novel
demonstration of the adaptive immune system influencing the production of natural antibodies. The results demonstrate
that injection of malondialdehyde-modified LDL promotes a Th2 response that in turn increases the titers of the natural
antibody T15/EO6, which recognizes the oxidized phospholipid POVPC. Atherosclerotic lesion size in LDL receptor–
deficient mice is reduced as a consequence of the increase in natural antibody titers, and IL-5 is identified as the link
between the adaptive and natural immune systems.
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IL-5 links adaptive and natural immunity
in reducing atherosclerotic disease
Alan Daugherty, Debra L. Rateri, and Victoria L. King
Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA.

Oxidized LDL induces changes in several facets of the immune system,
although the relationships between these facets and their contributions to
atherogenesis have yet to be fully elucidated. A report in this issue of the JCI
provides a novel demonstration of the adaptive immune system influencing
the production of natural antibodies. The results demonstrate that injection
of malondialdehyde-modified LDL promotes a Th2 response that in turn
increases the titers of the natural antibody T15/EO6, which recognizes the
oxidized phospholipid POVPC. Atherosclerotic lesion size in LDL receptor–deficient mice is reduced as a consequence of the increase in natural antibody titers, and IL-5 is identified as the link between the adaptive and natural
immune systems (see related article beginning on page 427).
Several decades ago it was proposed that oxidative modification of LDL promoted the
formation of atherosclerotic lesions (1). Early
studies focused on the ability of oxidized
LDL (OxLDL) to bind macrophage scavenger receptors as a mechanism for the formation of lipid-laden foam cells that are present
throughout the evolution of atherosclerotic
lesions. Subsequent studies have demonstrated that oxidatively modified LDL is a
complex entity with a range of atherogenic
properties that affect macrophages. These
include promotion of macrophage recruitment and retention, lipid loading via multiple receptor types, induction of inflammatory genes, and cell viability (2).
Although the role of macrophages initially took center stage in atherosclerosis
research, there is a growing literature on
the interaction of OxLDL with both the
cell-mediated and humoral components
of the adaptive immune system. Cell-mediated responses were demonstrated following OxLDL stimulation of T lymphocyte
clones isolated from atherosclerotic lesions
(3). In addition, many studies have demonstrated humoral immune responses in
reaction to the presence of autoantibodies
to specific forms of OxLDL, particularly
malondialdehyde-modified LDL (MDANonstandard abbreviations used: malondialdehydemodified LDL (MDA-LDL); oxidized LDL (OxLDL);
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine (POVPC).
Conflict of interest: The authors have declared that no
conflict of interest exists.
Citation for this article: J. Clin. Invest. 114:317–319
(2004). doi:10.1172/JCI200422561.

LDL) (4). Although autoantibodies to
OxLDL are consistently found in hyperlipidemic animals and humans, their impact
on the atherosclerotic process is unclear.
Higher titers of these autoantibodies often
positively correlate with severity of atherosclerosis, which led to conjecture regarding their involvement in the disease process. For example, titers of autoantibodies
to selected forms of OxLDL have been
shown to predict the severity of human
carotid atherosclerosis (5). To determine
whether these correlations were causal,
autoantibody titers were increased by
immunizing hyperlipidemic rabbits and
mice with different forms of modified LDL,
which produced an unanticipated result:
immunization with MDA-LDL actually
decreased the size of atherosclerotic lesions
in Watanabe heritable hyperlipidemic rabbits (6). Subsequent studies in rabbits and
mice have shown some anomalies in the
antibody isotypes developed during immunization but have consistently demonstrated a decrease in atherosclerotic lesion size
in response to immunization with different
forms of OxLDL (7, 8).
OxLDL autoantibodies
in apoE–/– mice
apoE–/– mice represent a widely used animal model of atherosclerosis, and they
develop autoantibody titers to modified
LDL independent of immunization (9).
Witztum and colleagues previously capitalized on this observation by creating a
panel of monoclonal antibodies from the
spleens of aged apoE–/– mice. This panel
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has proven to be invaluable for the identification of oxidative products formed
in these hyperlipidemic mice (10). All of
the characterized monoclonal antibodies
are IgMs. The most extensively characterized IgM anti-OxLDL antibody, EO6,
reacts against an oxidized phospholipid in
modified LDL that has been identified as
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3phosphorylcholine (POVPC). EO6 exerts
functional effects by binding selectively to
oxidized LDL and blocking macrophage
lipid accumulation (11). An interesting
extension of this story is the finding that
EO6 is indistinguishable from the natural
antibody T15, which is secreted by a specialized subclass of B lymphocytes termed
B-1 cells (12). Hence, this antibody is now
commonly referred to as T15/EO6. The
function of natural antibodies has not
been defined, but they are thought to represent part of an innate system that affords
protection from microorganisms. For
example, the T15 antibody confers protection from Streptococcus pneumoniae infection in mice. Binder et al. have previously
demonstrated a link between the T15 antibody and atherosclerosis by increasing T15
antibody titers by S. pneumoniae immunization and observing a concomitant reduction in atherosclerotic lesion size in LDL
receptor–deficient mice (13).
How does adaptive immunity
affect natural antibodies?
In this issue of the JCI, Binder et al. have
elucidated a mechanism of the paradox of
immunization with MDA-LDL producing
a T lymphocyte–dependent increase in the
titers of T15/EO6 antibodies and a reduction in the size of atherosclerotic lesions in
LDL receptor–deficient mice. Thus, activation of the adaptive immune system led to
a protective effect that was attributed to
augmentation of natural immunity. Furthermore, they identify IL-5 as the critical
link between these two distinct forms of
immune responses (Figure 1) (14).
Binder et al. demonstrate that immunization of wild-type C57BL/6 mice with MDA-
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Figure 1
The sequence of events elucidated by Binder
et al. (14) define the link between adaptive
and natural immunity in atherogenesis. MDALDL immunization of LDL receptor–deficient
mice led to a Th2 immune response. This was
demonstrated by the predominance of IgG1
isotype antibodies against MDA-LDL that were
generated during immunization. Also, antigen
challenge of splenocytes led to secretion of
the Th2 cytokines: IL-5, IL-10, and IL-13.
IL-5 secretion promoted an increase in titers
of natural antibodies, termed T15/EO6. These
antibodies recognize an oxidized phospholipid, POVPC, that is not present in the immunizing material. The T15/EO6 antibody has been
previously shown to inhibit OxLDL recognition
by macrophages, which may account for the
reduction in atherosclerotic lesion size.

B-1 cells; (b) intraperitoneal injections of
IL-5 into naive C57BL/6 mice increased T15/
EO6 titers; and (c) IL-5–deficient mice had
reduced T15/EO6 titers. Furthermore, the
IL-5 genotype had no effect on the titers of
IgG1 and IgG2a raised following immunization with MDA-LDL, while an IL-5 deficiency ablated the increased IgM titers elicited in
response to MDA-LDL immunization.

LDL led to a predominantly Th2 immune
response (14). Antigen challenge resulted
in the induction of MDA-LDL–specific
IgG1 isotype autoantibodies and the
release of IL-5 and IL-13 from splenocytes.
Immunization of hypercholesterolemic,
LDL receptor–deficient mice also led to
enhanced IgG1 autoantibody titers. This
production of IgG1 isotype autoantibodies
against MDA-LDL was noted previously
during severe hypercholesterolemia (15).
Immunization also led to a decrease in
atherosclerotic lesion size that was selective for the aortic root. Splenocytes from
these mice preferentially secreted selected
Th2 cytokines, including IL-5, IL-10, and
IL-13, when exposed to MDA-LDL. These
cytokines were secreted in equivalent mass
from splenocytes when antigen challenged
in the absence of costimulation with CD28.
318

However, in the presence of CD28 stimulation, IL-5 was the most highly secreted
cytokine from splenocytes in response to
MDA-LDL challenge. In addition, MDALDL immunization also produced an
increase in plasma concentrations of IL-5.
Other Th2 cytokines were not measured.
This increased adaptive immune response
to MDA-LDL was associated with elevated
titers of the T15/EO6 natural antibody. This
was unexpected since the POVPC epitope
recognized by T15/EO6 was not present in
the immunizing material (14). Basing their
ideas in part on the preferential secretion of
IL-5 promoted by MDA-LDL immunization,
the authors speculated that the release of
this cytokine augmented the production of
natural antibodies. This notion was supported by several observations including: (a) IL-5
promoted T15/EO6 secretion from cultured
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IL-5 regulates atherosclerotic
lesion size
The final step in this study was to define
the effect of IL-5 deficiency on the development of atherosclerosis. This was achieved
by irradiating LDL receptor–deficient mice
and reconstituting them with bone marrow–derived stem cells from either IL-5
wild-type or deficient mice (14). After an
engraftment period, mice were fed a highfat diet. The group reconstituted with bone
marrow–derived stem cells harvested from
IL-5 wild-type mice had decreased atherosclerotic lesion size. This decrease in lesion
size in mice secreting IL-5 occurred in
both the aortic root and the aortic intima
in contrast to the site-selective effects of
MDA-LDL immunization.
These studies establish a working paradigm for further research. This will include
determining whether MDA-LDL immunization has any effect on the development
of atherosclerosis in IL-5–deficient mice. It
will also be important to establish whether
IL-5 is the exclusive cytokine that links the
effects of adaptive and natural immunity
in atherogenesis. Other Th2 cytokines, particularly IL-10, have established antiatherogenic properties, although links to humoral
responses have not been elucidated (16–18).
Furthermore, the studies of Binder et al.
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(14) have demonstrated that the effects of
MDA-LDL immunization are associated
with increased titers of the IgM-antibody
isotype. However, future studies will need to
determine the relative contribution of T15/
EO6 IgMs to the reduction in atherosclerosis versus that of other IgMs that are formed
during MDA-LDL immunization. Finally, it
will be important to determine whether the
T15/EO6-mediated inhibition of OxLDL
uptake by macrophages observed in cultured cells is the mechanism responsible for
the reduced atherosclerotic lesion size.
Overall, these studies have mapped out an
interesting and novel pathway linking the
adaptive and natural arms of the immune
system (14). These findings also highlight a
practical issue that needs to be considered
for future therapeutic strategies. Specifically, antagonists of IL-5 are being developed
for asthma therapy. The studies of Binder
et al. indicate that it will be important to
determine the ramifications of such a therapy on vascular disease.
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Pulmonary fibrosis: thinking outside of the lung
Stavros Garantziotis,1 Mark P. Steele,1 and David A. Schwartz1,2
1Department

of Medicine at Duke University Medical Center; 2Durham Department of Veterans Affairs Medical Center, Durham, North Carolina, USA.

Pulmonary fibrosis is a devastating condition that leads to progressive lung
destruction and scarring. Previous mechanistic research has focused on the
local fibroproliferative process in the lung. However, emerging evidence suggests that circulating cells of hematopoietic origin play a crucial role in the
pathogenesis of this disease (see the related article beginning on page 438).
Idiopathic interstitial pneumonias (IIPs;
see Table 1) are a group of devastating conditions isolated to the lung and, except by
lung transplantation, often are untreatable. While idiopathic pulmonary fibrosis
(IPF) is the most common type of IIP and
involves dense fibrosis with active areas of
Nonstandard abbreviations used: CXC chemokine
ligand 12 (CXCL12); idiopathic interstitial pneumonia
(IIP); idiopathic pulmonary fibrosis (IPF).
Conflict of interest: D.A. Schwartz serves as a scientific
advisor for Intermune.
Citation for this article: J. Clin. Invest. 114:319–321
(2004). doi:10.1172/JCI200422497.

fibroproliferation, other forms of IIP are
characterized by varying degrees of inflammation in addition to the active fibroproliferative process. Although pulmonary
fibrosis has traditionally been thought to
develop in response to chronic inflammation in the lung parenchyma, emerging
evidence suggests that repeated exogenous
and endogenous stimuli cause sequential lung injury that results in pulmonary
fibrosis in individuals unable to effectively
heal the damage (Figure 1) (1).
The key to understanding the complex
pathogenesis of IIP may lie in the answers

The Journal of Clinical Investigation

http://www.jci.org

Volume 114

to two very simple questions: why is this
condition isolated to the lung, and do factors outside of the lung affect the pathogenesis of this disease?
Circulating fibrocytes and
pulmonary fibrosis
In this issue of the JCI, Phillips and colleagues (2) endeavor to answer these questions by identifying the circulating fibrocyte and chemokine gradients critical to
the fibroproliferative process in a murine
model of bleomycin-induced pulmonary
fibrosis. Fibrocytes are a unique population of circulating cells of hematopoietic
origin that produce ECM proteins (e.g.,
fibroblast-like collagen and vimentin and
myofibroblast-like α-smooth muscle actin)
and differentiate into myofibroblasts (3).
These cells are characterized by specific
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